Recursion to Acquire Exscientia for $688M in AI-Powered Deal
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
- Latest
- Trending
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Eva Chen, CEO of Trend Micro, advocates balancing security and business for future cybersecurity challenges.
Nvidia's Blackwell B200 GPUs face delays; liquid-cooled H200 now offered, minimizing AI server market disruption.
Nvidia and chip stocks surge over 6% as tech sector leads the market recovery after recent declines.
Analysts see opportunity in Nvidia, AMD stocks despite recent losses, expecting benefits from AI chip demand.
Stocks surged at the opening but saw steep declines by closing. Learn why tech, Disney, and bond yields impacted the ...
Luminar Technologies restructures $422M debt, extends its maturity, and secures $100M non-dilutive capital, aiming for profitability by 2030.
The Virtual Reality market is set to grow significantly by 2032, driven by increased R&D investment and technological advancements.
Samsung's 8-layer HBM3E chips pass Nvidia's tests, setting stage for potential supply in late 2024 amid rising AI demand.
Discover the latest in AI, cloud security, and emerging threats at Black Hat USA, including major presentations from NVIDIA and ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.